DPPA5 Inhibitors
DPPA5 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of DPPA5 (Developmental Pluripotency Associated 5), a protein that plays a key role in maintaining pluripotency in embryonic stem cells. DPPA5 is involved in regulating the self-renewal capacity of pluripotent cells, helping them remain undifferentiated by influencing gene expression patterns associated with early development. This protein is particularly expressed during the early stages of embryogenesis, where it helps preserve the undifferentiated state of stem cells. By inhibiting DPPA5, researchers aim to explore its contribution to maintaining the balance between stem cell self-renewal and differentiation, shedding light on how this protein modulates the pluripotent state.
The mechanism of action for DPPA5 inhibitors typically involves binding to the protein's functional domains that are essential for its interaction with other regulatory molecules or RNA-binding proteins. By blocking these interactions, DPPA5 inhibitors can disrupt the molecular networks that DPPA5 helps regulate. Structurally, these inhibitors may mimic natural substrates or binding partners, competing with them for binding sites on DPPA5, or they might induce conformational changes that deactivate the protein's function. Through the use of DPPA5 inhibitors, researchers can investigate the role of this protein in the regulation of gene expression linked to pluripotency and differentiation, offering insights into the mechanisms that govern early developmental processes. These inhibitors are valuable tools for understanding how cellular plasticity and pluripotency are controlled at the molecular level and how specific proteins like DPPA5 influence these critical biological functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This nucleoside analogue could interfere with the methylation status of the DPPA5 gene's promoter, leading to transcriptional silencing and a subsequent decrease in its expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
By inhibiting DNA methyltransferases, 5-Aza-2′-Deoxycytidine could lead to demethylation of the DPPA5 gene promoter, which may result in transcriptional repression and a decrease in DPPA5 levels. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
This compound can disrupt histone deacetylase activity, leading to an accumulation of acetylated histones, which could repress transcription initiation at the DPPA5 gene and consequently decrease its expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
As a histone deacetylase inhibitor, this compound might cause hyperacetylation of histones near the DPPA5 gene locus, potentially leading to transcriptional repression and a reduction in DPPA5 protein synthesis. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
By disrupting histone deacetylase enzymes, Suberoylanilide Hydroxamic Acid could cause alterations in the chromatin structure at the DPPA5 gene, leading to a downregulation of its transcription. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A could bind selectively to the DPPA5 gene promoter and obstruct the binding of transcription factors, thereby inhibiting the transcription and decreasing DPPA5 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
This compound could bind to retinoic acid receptors that interact with the DPPA5 gene regulatory regions, potentially inhibiting transcriptional initiation and reducing the level of DPPA5 production. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could inhibit the mTOR pathway, which may be necessary for the translation of certain mRNAs, including potentially those for DPPA5, leading to a decrease in DPPA5 protein levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
By inhibiting PI3K, LY 294002 could downregulate AKT signaling, which may be involved in the transcriptional control of the DPPA5 gene, resulting in reduced expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This MEK inhibitor could decrease ERK pathway signaling, which could be involved in the control of transcriptional regulation machinery for DPPA5, leading to reduced expression. | ||||||